Planning for the implementation of new diagnostic tests
|
|
- Shona Walters
- 5 years ago
- Views:
Transcription
1 Planning for the implementation of new diagnostic tests Dr Christopher Gilpin Laboratories, Diagnostics & Drug Resistance WHO Global TB Programme, Geneva GLOBAL TB PROGRAMME Workshop on the development of National Strategic Plans for TB Control 1 Divonne, France, February 18 th 2014
2 The Global Burden of TB Estimated number of cases Estimated number of deaths All forms of TB HIV-associated TB 8.6 ( ) million 1.3 ( ) million* 0.5 m in children in children 3 million 2.9 m cases in women missed in women 1.1 ( ) million (13%) 320,000 (300k-340k) Multidrug-resistant TB (300k-600k) 170,000 (102k-242k) Source: WHO Global Tuberculosis Report * Including deaths attributed to HIV/TB
3 Outline WHO requirements for evaluation of new TB diagnostics Diagnostic pipeline Levels of laboratory services Diagnostic tools what is necessary? Forecasting and quantification based on country specific edpidemiology Maintenance Technical assistance
4 Evidence required for WHO review of diagnostics Phase 5 Scale-up and policy refinement Phase 1 Research and Development Phase 4 Phased uptake and collection of evidence for scale-up Phase 2 Evaluation and Demonstration Phase 3 WHO evidence assessment GRADE
5 Pipeline for new TB diagnostics
6 PROGRESS AT A GLANCE 2013 Global Report Volatile Organic Compounds BreathLink, Menssana Research, USA Prototype breathanalyzer device, Next Dimensions Technology, USA Molecular Detection MTB and drug resistance Alere Q, Alere, USA B-SMART, LabCorp, USA Gendrive MTB/RIF ID, Epistem, UK LATE-PCR, Brandeis University, USA GeneXpert XDR cartridge, Cepheid, USA TruArray MDR-TB, Akkoni, USA INFINITIMTB Assay, AutoGenomics, USA Nonmolecular technologies TB Rapid Screen, Global BioDiagnostics, USA TBDx, Signature Mapping Medical Sciences, USA Culture-based technologies BNP Middlebrook, NanoLogix, USA MDR-XDR TB Color Test, FIND, Switzerland / Imperial College, UK TREK Sensititre MYCOTB MIC plate, Trek Diagnostic Systems/ Thermo Fisher Scientific, USA Molecular Detection MTB +/- drug resistance TB LAMP, Eiken, Japan Genotype MTBDRsl, Hain Lifescience, Germany Molecular Detection MTB and drug resistance icubate System, icubate, USA TB drug resistance array, Capital Bio, China NATeasy TB Diagnostic kit, Ustar Biotechnologies, China Truelab/Truenat MTB, Molbio/bigtec Diagnostics, India Nonmolecular technologies Alere Determine TB-LAM, Alere, USA Commercial serodiagnostics (ALL MANUFACTURERS) Interferon-gamma release assays for the detection of active TB (ALL SETTINGS) Molecular Detection of MTB and drug resistance Xpert MTB/RIF (pulmonary extrapulmonary and paediatric samples) Lineprobe assays for the detection of MTB and rifampicin resistance conferring mutations in AFB smear positive sputum or MTB cultures Microscopy Light and LED Microscopy Same-day -diagnosis Culture-based technologies Commercial liquid culture systems and rapid speciation Non-commercial culture and DST (MODS, NRA, CRI)
7 Technologies endorsed by WHO MTB and drug resistance Xpert MTB/RIF (pulmonary extrapulmonary and paediatric samples) Lineprobe assays for the detection of MTB and rifampicin resistance conferring mutations in AFB smear positive sputum or MTB cultures Microscopy Light and LED Microscopy Same-day -diagnosis Culture-based technologies Commercial liquid culture systems and rapid speciation Non-commercial culture and DST (MODS, NRA, CRI)
8 WHO recommended diagnostics for use at different levels of laboratory sophistication *Available at:
9 Biosafety Levels for TB Laboratories High TB risk precautions Culture, DST, LPA (cultures) Moderate TB risk precautions liquifying (processing) samples Low TB risk precautions Microscopy, Xpert
10 High TB Risk Precautions TB containment laboratory Double door airlock Separate air inlet Venting of BSC via thimble Aerosol containment Negative pressure monitoring Uni-directional airflow PPE Autoclave for waste disposal Necessary for performing culture and DST
11 Why perform culture? Culture in Liquid media up to six weeks Reference method Culture on solid media up to eight weeks Given the diagnostic delay culture is NOT a good diagnostic tool Essential for performing DST to second-line drugs Necessary for monitoring patient response to treatment
12 Complexity of performing sputum culture and line probe assays 1. Liquefaction 2. Sample decanted 3. Decontamination NaOH 4. Vortex 5. Phosphate Buffer 6. Centrifugation 7. Decant 8. Re-suspend 9. Inoculation 12
13 Why perform LPA? LPA can be used to detect rifampicin and isoniazid conferring mutations in AFB smear positive specimens Positive TB cultures Results can be available in 24 hrs Secondline LPA NOT recommended Needs sophisticated laboratory Needs good referral mechanisms Suitable for high throughput testing at Central or Regional laboratory level
14 CC AC TUB rpob rpob rpob rpob rpob rpob rpob rpob rpob rpob rpob rpob rpob WT1 WT2 WT3 WT4 WT5 WT6 WT7 WT8 MUT1 MUT2A MUT2B MUT3 katg katg WT katg MUT1 katg MUT2 inha inha inha inha inha inha inha TUB WT1 WT2 MUT1 MUT2 MUT3A MUT3B rpob MUT katg WT katg MUT inha WT inha MUT sensitive resistant sensitive resistant Additional infrastructure for LPA 1. Laboratory infrastructure to address biosafety and contamination control 1. Containment laboratory for DNA extraction 2. At least two additional rooms needed for DNA pre-amplification and post-amplification processes 2. Appropriately well train staff supervised by experience technologists in molecular biology 3. Multiple pieces of equipment 4. Stringent laboratory protocols needed SOPs, Internal QC, External QA, # katg RMP INH rpob inha
15 Why perform Xpert MTB/RIF 1. Laboratory infrastructure similar to that for microscopy is required 2. Can be de-centralised for testing at lower levels of the laboratory network 3. Suitable for the diagnosis of TB and rifampicin resistance in AFB smear-negative and smear-positive individuals 4. New WHO policy recommendations issued for use in adults children and extrapulmonary TB
16 Individuals to test using Xpert MTB/RIF All individuals presumed to have TB Initial TB diagnostic test Xpert MTB/RIF should be used rather than conventional microscopy, culture and DST as the All individuals at initial diagnostic test in adults presumed to have MDR-TB or HIV-associated TB risk of MDR-TB (TB A. (strong recommendation, high-quality Strong recommendation evidence). confirmed and TB Xpert MTB/RIF Xpert suspected) MTB/RIF should be used rather than conventional microscopy, culture and DST as the initial diagnostic test in children presumed to have MDR-TB or HIV-associated TB (strong recommendation, very low-quality evidence). HIV (+) individuals Xpert (or MTB/RIF HIV unknown may be used in rather than conventional microscopy and culture as the initial diagnostic Xpert MTB/RIF B. high test HIV in settings) all adults presumed Strong recommendation to have TB (conditional recommendation acknowledging resource suspected implications, of high-quality evidence). Xpert having MTB/RIF TB may be used rather than conventional microscopy and culture as the initial diagnostic test in all children presumed to have TB (conditional recommendation acknowledging resource implications, very low-quality evidence). Conditional recommendation Xpert Adults MTB/RIF presumed may be used to as a follow-on test to microscopy in adults presumed to have TB C. but not have at risk TB of but MDR-TB not at or HIV Conditional associated TB, especially Smear in further Smear testing of smear-negative microscopy neg. Xpert MTB/RIF specimens risk of (conditional MDR-TB or recommendation acknowledging resource implications, high-quality evidence). HIV associated TB
17 Interpretation of test results Xpert MTB/RIF assay TB not detected In groups with high risk of MDR-TB TB detected; Rif resistant TB detected; Rif sensitive WHO recommended regimen for MDR-TB with INH; Registration as RR-TB DST to at least INH; Quinolones; SL injectable In groups with low risk of MDR-TB Repeat Xpert MTB/RIF WHO recommended first-line treatment; Registration as bacteriologically confirmed TB Modify treatment based on the DST results; Update registration TB detected; Rif resistant TB detected; Rif sensitive WHO recommended regimen for MDR-TB with INH; Registration as RR-TB DST to at least RIF; INH; Quinolones; SL injectable Modify treatment based on the DST results; Update registration In case of discordance on Rif result refer sample for sequencing If TB still suspected Further investigation (CXR, repeat Xpert MTB/RIF, culture, etc..)
18 National strategy and objectives Which diagnostic algorithm will be implemented? Procurement planning is directly linked to the National TB Plan What infrastructure needs to be established or upgraded? How many labs? At which level? Which diagnostics will be used? At which level - peripheral, district, regional, central? Planning for infrastructure improvement Planning for procurement of goods (shelf-life) Quantifying and forecasting needs Developing a supply chain (cold) for TB laboratories Is a specimen transport and referral system adapted to this new plan?
19 WHO TB Planning and budgeting tool Ready-made framework for planning/budgeting for each component of TB control Application options to enhance user-friendliness Choosing country via menu system selects correct set of epidemiology/ demographic/financial historical data, projections and default values Menu driven system Summary tables and figures automatically produced Guidance available within tool
20 Example: Pakistan # MDR patients (projections)
21 What diagnostics are needed for previously treated patients? Need estimates of the number of previously treated persons based on case notifications. Need to estimate proportion of rifampicin resistance e.g Pakistan 14,000 previously treated persons 30% Rifampicin resistance among previously treated 3% Rif resistance among new cases 14,000 persons require a rapid DST Xpert MTB/RIF or LPA 4,200 persons (30% of 14,000)(MDR-TB patients) will require culture and DST for secondline drugs Each person will require additional cultures for monitoring response to therapy up to 12 cultures per person or 50,400 cultures Need many more Xpert tests to detect 3% RIF resistance among new cases aim for 20% by 2015
22 What diagnostics are needed for previously treated patients? 14,000 persons require a rapid DST Xpert MTB/RIF or LPA The structure of the laboratory network and referral mechanism will determine which tests to use where. If network is well structured testing can be de-centralised and test previously treated persons using Xpert If only the central level is strong a larger proportion of the tests could be referred to the central level for testing by LPA(where capacity already exists) A combination of specimen referral for LPA and decentralized Xpert testing can be used
23 What diagnostics are needed for person with HIV? Indicator Source Remarks a Annual projected number of HIV positive (adult and children) in care at a clinic, (pre-art and ART) based on a baseline figure (2012) National HIV program (user entry) HIV in care includes HIV treatment, i.e. enrolment in the pre-art register or in the ART register once started on ART. Projections are based on 2012 baseline data. b c Assumption % of HIV positive (adult and children) in care at a clinic are screened Assumption 2. 15% of HIV positive (adult and children) in care at a clinic screened and with presumptive TB User can modify this assumption based on the coverage of TB screening among PLHIV Assumption based on expert group decision for the Spectrum model The TB screening should be done based on national TB/HIV guidelines. This assumption is based on a premise of rule-in TB in order to increase the suspicion of having TB in PLHIV. d Assumption 3. % coverage of Xpert testing for the 15% HIV positive presumed to have TB User entry: based on the capacity to scale up Xpert testing e Estimated number of HIV positive patients tested with Xpert Calculated e= a*b*c*d Default formula appears in costing tool
24 What diagnostics are needed for Annual projected of the number of HIV positive persons in care Assume: 100% screening Assume: 15% with presumptive Consider % coverage of Xpert person with HIV? e.g Africa context 100,000 PLHIV in care Need to test 20-30% have symptoms of TB Up to 30,000 persons will require a rapid diagnostic test Xpert MTB/RIF (depending on Xpert coverage) Assuming 3% MDR-TB among new cases of TB in PLHIV Up to 900 persons (MDR-TB patients) will require culture and DST for secondline drugs Each person will require additional cultures for monitoring response to therapy up to 12 cultures per person or 10,800 cultures
25 Planning for facility maintenance Annual certification of BSC Costs vary depending on setting Centrifuge maintenance GeneXpert module calibration Autoclave Monitoring integrity of ducted exhaust Building maintenance Need to consider approx. 10% of facility cost needed for annual maintenance
26 Technical Assistance Collaboration agreements Quality assurance Appropriate biosafety Diagnostic algorithms Functional networks Rational planning with laboratory experts
27 Acknowledgements Laboratory, Diagnostics and Drug Resistance unit in the WHO Global TB Programme: Karin Weyer, Fuad Mirzayev, Wayne van Gemert, Jean Iragena, Fraser Wares, Ernesto Jaramillo, Dennis Falzon, Vineet Bhatia, Henriikka Huttunen, Lynne Harrop, Diego Zallocco
28 Xpert MTB/RIF What is needed? A Item Cost Comment GeneXpert 4 module with laptop (Ex-Works price) Equipment C UPS $1, $17, >60% price reduction compared to EU/US B Shipment $1, Depends on destination Local purchase, price depends on the market and back up capacity of UPS D Printer $ E Maintenance Annual calibration costs $1, Local purchase, price depends on the market, optional Highest price if done in Cepheid Toulouse, when web-based drops to 450USD F G H I J Consumables Cost per cartridge $ % price reduction compared to EU Number of working days per year Average number of tests per instrument /day Number of tests/1 year/ full load 1 instrument Losses due to error/incorrect use (high estimate 10%) 250 Number can vary depending on local context 12 Number can vary depending on working hours 3000 G*H % of I K HR costs Technician annual salary $5, Country-specific L Training and TA $5, Depends on the needs M N Installation costs Running costs (annual, 1 instrument) $19, A+B+C+D $34, E+F*(I+J) O GRAND TOTAL $64, N+M+L+K
: uptake and impact of Xpert MTB/RIF
Photo: Riccardo Venturi 21-215: uptake and impact of Xpert MTB/RIF Wayne van Gemert WHO Global TB Programme, Geneva Joint Partners Forum for Strengthening and Aligning TB Diagnosis and Treatment 27-3 April
More informationHow best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms Revised June 2018 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationDST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?
DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps? Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms March 2017 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient access
More informationChallenges in Capacity in SA for diagnosing DR-TB
National Tuberculosis Reference Laboratory Challenges in Capacity in SA for diagnosing DR-TB March 2010 Gerrit Coetzee Rapid response to XDR-TB WHO Global Task Force on XDR-TB, October 2006 Accelerate
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationMultidrug-Resistant TB
Multidrug-Resistant TB Diagnosis Treatment Linking Diagnosis and Treatment Charles L. Daley, M.D. National Jewish Health University of Colorado Denver Disclosures Chair, Data Monitoring Committee for delamanid
More informationTreating Patients, Not Disease: People-Centered Approach
Treating Patients, Not Disease: People-Centered Approach 7th Annual TB Symposium Ministry of Health of the Kyrgyz Republic and Médecins Sans Frontières 1-2 March, 2018, BISHKEK, KYRGYZSTAN TB Diagnostics
More informationA roadmap for TB laboratory strengthening within WHO policy frameworks and national laboratory strategies
2 nd Annual GLI Meeting Annecy, 15-16 October 2009 A roadmap for TB laboratory strengthening within WHO policy frameworks and national laboratory strategies Karin Weyer, WHO On behalf of the GLI Core Group
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationOnline Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationPOSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH
POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH Akos Somoskövi, M.D., Ph.D. and Giorgio Roscigno, M.D. ANNUAL GLI MEETING, 4 th OCTOBER 2010 MERIEUX FOUNDATION, ANNECY Integrated Laboratory Network
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of tuberculosis and multidrug-resistance GLOBAL CONSULTATION
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of tuberculosis and multidrug-resistance GLOBAL CONSULTATION Date and time: 30 November - 2 December 2010 Venue: Centre International
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationXpert MTB/RIF assay validation experience --- impact and plan in China
Xpert MTB/RIF assay validation experience --- impact and plan in China Dr. Zhao Yanlin Chinese Center for Disease Control & Prevention Dr. Richard O Brien FIND April. 16, 2013 Progress Contribution for
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationXpert MTB/RIF. implementation manual. Technical and operational how-to : practical considerations IMPLEMENTATION MANUAL TUBERCULOSIS PERFORMANCE
Xpert MTB/RIF implementation manual Technical and operational how-to : practical considerations TB NEW DIAGNOSTIC TESTS IMPLEMENTATION MANUAL DRUG-RESISTANCE TB/HIV RAPID TB TEST TUBERCULOSIS ACCURACY
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationAUTOMATED REAL-TIME NUCLEIC ACID AMPLIFICATION TECHNOLOGY FOR RAPID AND SIMULTANEOUS DETECTION OF TUBERCULOSIS AND RIFAMPICIN RESISTANCE:
AUTOMATED REAL-TIME NUCLEIC ACID AMPLIFICATION TECHNOLOGY FOR RAPID AND SIMULTANEOUS DETECTION OF TUBERCULOSIS AND RIFAMPICIN RESISTANCE: Xpert MTB/RIF SYSTEM POLICY STATEMENT WHO Library Cataloguing-in-Publication
More informationHIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationMinistry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)
Ministry of Health National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015) Contents Executive summary... 2 Background... 3 National Tuberculosis Program Overview... 3
More informationPolicy Framework for Implementing New Tuberculosis Diagnostics
Policy Framework for Implementing New Tuberculosis Diagnostics March 2010 Table of Contents Executive summary...2 Abbreviations...1 Introduction...2 WHO policy on new technology is evidence-driven...2
More informationXpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work
Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection Results of Group Work DOTS expansion and enhancement Objective This group deals with the majority
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationXpert MTB/RIF test Rollout and Implementation Plan
Xpert MTB/RIF test Rollout and Implementation Plan UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME 6 Samora Machel Avenue P.O. Box 9083 11478
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2019, Vol. 5, Issue 2, 01-06 Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 5.008 COMPARATIVE STUDY BETWEEN GENEXPERT MTB/RIF ASSAY AND DIRECT SMEAR MICROSCOPY(DSM) FOR
More informationTowards Harmonization of Mycobacteriology in TB Trials. Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory Procedures
Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory Procedures: Towards Harmonization of Mycobacteriology in TB Trials Title Author(s) Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationTB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012
TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationDiagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm
Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm Kathryn Schnippel 1, Gesine Meyer-Rath 1,2, Lawrence Long 1, Wendy Stevens 3,4, Ian Sanne 1,2, and Sydney Rosen
More informationRapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
REVIEW RAPID MOLECULAR TB DIAGNOSIS Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF Karin Weyer 1, Fuad Mirzayev 1, Giovanni Battista Migliori 2, Wayne
More informationCosting of the Sierra Leone National Strategic Plan for TB
Costing of the Sierra Leone National Strategic Plan for TB 2016-2020 Introduction The Government of Sierra Leone established the National Leprosy Control Programme in 1973 with support from the German
More informationXpert MTB/RIF Training. Indira Soundiram 2012
Xpert MTB/RIF Training Indira Soundiram 2012 A Better Way to Platform Design GeneXpert Infinity-48 GeneXpert Module GX-I GX-II GX-IV GX-XVI 2 Defining Molecular Diagnostics Any Test Any Time Any Sample
More informationSchedules of different training programs planned at NITRD under this WHO CC are given in the NITRD-WHOCC Training Schedules booklet.
WHO Collaborating Centre in Tuberculosis Training National Institute of Tuberculosis and Respiratory Diseases has been designated by the WHO as a WHO Collaborating Centre in Tuberculosis Training on 06
More informationDetection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1543-1549 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.185
More informationHeather Alexander, PhD
Xpert MTB/RIF: An Opportunity to Strengthen Laboratory Systems and Bridge the Laboratory-Program Gap Heather Alexander, PhD International Laboratory Branch Division of Global HIV/AIDS Centers for Disease
More informationAutomated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance:
Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014
TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationReceipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen
Recommendation Promote rapid delivery of specimens to the laboratory Use fluorescent acid-fast staining and promptly transmit results by phone, FAX, or electronically Identify growth as acid-fast and use
More informationINTENSIFIED TB CASE FINDING
INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationMolecular assays in Tuberculosis. Jatin Yegurla Junior resident
Molecular assays in Tuberculosis Jatin Yegurla Junior resident 17-3-2018 Contents Introduction TB-PCR Line Probe assay (LPA) GenoType MTBDRsl test (Second line LPA) Xpert MTB/RIF (GeneXpert) (CB-NAAT)
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationProcurement update: StopTB Partnership - Global Drug Facility (GDF)
Procurement update: StopTB Partnership - Global Drug Facility (GDF) Magali BABALEY Strategic Procurement and Business Intelligence Manager Stop TB Partnership, Global Drug Facility (GDF) team joint UNICEF-UNFPA-WHO
More informationMIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex
MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex Marie Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More information2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:
The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.
More informationTechnology and innovation: Changing dynamics of TB control. Karin Weyer
Technology and innovation: Changing dynamics of TB control Karin Weyer Latest news 1. New tools finally a reality 2. Universal access for all affected from TB 3. Emphasis on early case detection and treatment
More informationHealth Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)
Health Care Worker Training on Roll Out New TB Diagnostic Test Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien) Overview Specimen Collection Investigations to request Sorting & registering
More informationSoedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital There were an estimated 10.4 million new TB cases in 2015, higher than
More informationAN ACTIVIST S GUIDE TO. Tuberculosis Diagnostic Tools
AN ACTIVIST S GUIDE TO Tuberculosis Diagnostic Tools FEBRUARY 2017 This guide was written by Khairunisa Suleiman and edited by Erica Lessem. Thanks to Bryn Gay (Treatment Action Group) and Dr. Wayne van
More informationProgress Report March 2016
Progress Report March 2016 Table of Contents Background to project 3 Assays performed to date 3 Correctional Services 5 Peri-Mining 6 Rif Concordance 7 Training: Laboratory and Clinical 7 Challenges identified
More informationStacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona
Role of the Laboratory in TB Diagnosis Stacy White, PhD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Stacy White, PhD has the following disclosures
More informationReport of TB/HIV Diagnostics Task Force. Barbara Laughon NIAID, NIH
Report of TB/HIV Diagnostics Task Force Barbara Laughon NIAID, NIH TB/HIV Diagnostics Task Force STOP TB WG on New Diagnostics reorganized with liaisons from other WG A statement of needs requested from
More informationRevised National Tuberculosis Control Programme
Revised National Tuberculosis Control Programme 1 OUTLINE OF PRESENTATION Introduction Burden Of The Disease Evolution Of RNTCP Goals And Objectives Of RNTCP DOTS Stop TB Strategy Organization RNTCP Endorsed
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationThe New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations
Workshop to accelerate the implementation of the Three Is for HIV/TB and earlier initiation of ART in Southern Africa, March 14-18, 2011, Johannesburg, South Africa. The New WHO guidelines on intensified
More informationPlanning for country transition to Xpert MTB/RIF Ultra Cartridges
Planning for country transition to Xpert MTB/RIF Ultra Cartridges Planning for country transition to Xpert MTB/RIF Ultra cartridges April 2017 Contents Acknowledgements About this guide Target audience
More informationLaboratory Diagnosis for MDR TB
Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe
More informationDiagnosis of HIV-Associated Tuberculosis
Diagnosis of HIV-Associated Tuberculosis Stephen D. Lawn Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine University of Cape Town Dept. Of Clinical Research, Faculty of Infectious
More informationTargeting HIV Settings Through PEPFAR. Bill Coggin, OGAC PEPFAR Laboratory Technical Working Group
Targeting HIV Settings Through PEPFAR Bill Coggin, OGAC PEPFAR Laboratory Technical Working Group PEPFAR Laboratory Program is a Critical part of Health Systems Strengthening Mission: To support countries
More informationIntroduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24
Diagnosis of extrapulmonaryand paediatric tuberculosis AW Dreyer Centre for Tuberculosis NICD Introduction Part of the global efforts to control tuberculosis (TB) include improving case detection, especially
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationUGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME
MINISTRY OF HEALTH UGANDA TIOL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME Revised Strategic Plan 2015/16-2019/20 Monitoring and Evaluation Plan Narrative of the Operational, Budget and Technical Assistance
More informationCULTURE OR PCR WHAT IS
CULTURE OR PCR WHAT IS BEST FOR AFRICA? Peter R Mason BRTI TB IN AFRICA GLOBAL 9 MILLION NEW CASES/YR 1.5 MILLION TB DEATHS AFRICA 95% TB DEATHS IN LMIC 9/22 HIGH BURDEN COUNTRIES IN AFRICA STRONG LINK
More informationNAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL
NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL Susan Novak-Weekley, S(M), ASCP, Ph.D., D(ABMM) Director of Microbiology,
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationTB Diagnostics: Global Market Analysis and Potential
TB Diagnostics: Global Market Analysis and Potential Madhukar Pai, MD, PhD McGill University, Montreal, Canada madhukar.pai@mcgill.ca September 2012 Market analyses are important and necessary To support
More informationNational Xpert MTB/RIF Programme
National Xpert MTB/RIF Programme 1. Background to Project This project was initiated at the request of the Honorable Minister of Health, Dr Aaron Motsoaledi, in early 2011, following the World Health Organization
More informationThe innovation gaps and challenges for MDR-TB. Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board
The innovation gaps and challenges for the diagnostic and treatment of TB and MDR-TB Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board Diagnosis Overview of
More informationPiloting Rational Introduction of New TB Medicines
Piloting Rational Introduction of New TB Medicines CPTR Meeting Emerging Issues in Global Regulatory Pathways for TB Drug Regimen Development and Evaluation Washington DC, 25 th Sept 2014 Christian Lienhardt
More informationIndia s Contribution in Rolling out Newer and Rapid Diagnostics towards PMDT Scale-up
India s Contribution in Rolling out Newer and Rapid Diagnostics towards PMDT Scale-up Balasangameshwara Vollepore, FIND (India) FIND and Partners Symposium 43 rd Union World Conference on Lung Health November
More informationNew frontiers: Innovation and Access
8th Regional TB Symposium Tashkent, Uzbekistan Prof. L.N. Chernousova Central Tuberculosis Research Institute (CTRI) Ministry of Health of the Republic of Uzbekistan 28 February 1 March, 2019 1970 1975
More informationThe Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida
The Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida Calin B. Chiribau, 1 M-C. Rowlinson, 1 S.Crowe, 1 B. Jones, 1
More informationCosts of Novel Tuberculosis Diagnostics Will Countries Be Able to Afford It?
SUPPLEMENT ARTICLE Costs of Novel Tuberculosis Diagnostics Will Countries Be Able to Afford It? Andrea Pantoja, 1 Sandra V. Kik, 2 and Claudia M. Denkinger 3 1 Independent consultant for FIND, Zürich,
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationXpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10 Introduction Excellent performances, rapid results, and easy to use Questions Where and how are we going
More informationMolecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationResearch Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal
Hindawi International Scholarly Research Notices Volume 2017, Article ID 1635780, 5 pages https://doi.org/10.1155/2017/1635780 Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant
More informationClinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis
Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Amit S. Chitnis, MD, MPH; Pennan M. Barry, MD, MPH; Jennifer M. Flood, MD, MPH. California Tuberculosis Controllers
More informationAlere q A Molecular Platform for Global Health Diagnostics
Alere q A Molecular Platform for Global Health Diagnostics Glenn Johns, Ph.D. Director, Global Health Diagnostics R&D 6 th Advanced Course on Diagnostics Annecy, France September 9, 2015 Alere q Complete
More informationAfrican Society for Laboratory Medicine
African Society for Laboratory Medicine Strategic Planning for Scaling Up HIV Diagnostics for 90/90/90 WHO/UNAIDS MEETING WITH DIAGNOSTIC MANUFACTURERS AND STAKEHOLDERS March 10-11, 2016 Planning and Forecasts
More informationStrengthening and aligning diagnosis and treatment of drug-resistant TB in Russian Federation
LOGO Strengthening and aligning diagnosis and treatment of drug-resistant TB in Russian Federation Irina A.Vasilyeva Chief TB Specialist of the Russian Ministry of Health Central TB Research Institute,
More informationDiagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology: A Short Review
International Journal of Advanced Microbiology and Health Research www.ijamhr.com Volume 1; Issue 1; September 2017; Page No. 20-24 Review Article Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology:
More informationDepartment Of AIDS Control (DAC) Ministry of Health and Family Welfare, GOI Chandralok Building, 36 - Janpath, New Delhi
Department Of AIDS Control () Ministry of Health and Family Welfare, GOI Chandralok Building, 36 - Janpath, New Delhi - 110001 Minutes of Meeting of National TB/HIV Co-ordination Committee (NTCC) held
More informationHigh-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting
Meeting Report High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting 28 29 April 2014 Geneva, Switzerland Meeting Report High-priority target product profi
More informationCBNAAT: A Novel Tool for Rapid Detection of MTB and Rifampicin Resistance
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 12 (2016) pp. 383-388 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.512.042
More informationMultidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017
Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant
More informationCLINICAL EXPERIENCE OF TREATING XDR- TB AT JOSE PEARSON TB HOSPITAL
CLINICAL EXPERIENCE OF TREATING XDR- TB AT JOSE PEARSON TB HOSPITAL BY DR LIMPHO RAMANGOAELA B.Sc.Ed(NUL),MBCHB(UKZN) 20 TH OCTOBER 2017 Livingstone Resource Centre. JOSE PEARSON TB HOSPITAL Out Line Overview
More informationEXPERT GROUP MEETING REPORT
Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children DRUG-RESISTANCE TB/HIV RAPID TB TEST TUBERCULOSIS ACCURACY RECOMMENDATIONS
More information